The quarter revealed troubling margin compression, with operating profit margin (excluding other income) contracting sharply to 43.77% from 49.14% in the previous quarter. On a year-on-year basis, net profit fell 9.25% from ₹12.00 crores in Q4 FY25, whilst revenue grew 17.20%, highlighting a significant deterioration in profitability despite top-line expansion.
The pharmaceutical manufacturer, promoted by Kantilal Shah and jointly owned by Yuhan Group (South Korea) and Pharmaceutical Business Group (India) Ltd., has seen its quality assessment upgraded to "Good" in recent quarters, yet operational performance in Q4 FY26 raises concerns about the sustainability of its premium valuation of 88x price-to-earnings ratio.
| Quarter | Revenue (₹ Cr) | QoQ Growth | Net Profit (₹ Cr) | QoQ Growth | Operating Margin | PAT Margin |
|---|---|---|---|---|---|---|
| Mar'26 | 44.23 | +1.98% | 10.89 | -12.60% | 43.77% | 24.62% |
| Dec'25 | 43.37 | +2.41% | 12.46 | -12.62% | 49.14% | 28.73% |
| Sep'25 | 42.35 | +18.07% | 14.26 | +57.40% | 49.47% | 33.67% |
| Jun'25 | 35.87 | -4.95% | 9.06 | -24.50% | 38.78% | 25.26% |
| Mar'25 | 37.74 | -4.50% | 12.00 | -7.48% | 42.50% | 31.80% |
| Dec'24 | 39.52 | +13.82% | 12.97 | +22.70% | 47.72% | 32.82% |
| Sep'24 | 34.72 | — | 10.57 | — | 44.35% | 30.44% |
Financial Performance: Margin Erosion Overshadows Revenue Gains
Gujarat Themis Biosyn's Q4 FY26 results present a concerning picture of margin deterioration despite achieving record quarterly revenue. Net sales of ₹44.23 crores represented modest sequential growth of 1.98% from ₹43.37 crores in Q3 FY26, but marked a solid 17.20% year-on-year increase from ₹37.74 crores in Q4 FY25. However, this top-line expansion failed to translate into bottom-line growth.
The operating profit margin (excluding other income) contracted sharply to 43.77% in Q4 FY26 from 49.14% in the previous quarter, representing a substantial 537 basis points compression. This margin stood at ₹19.36 crores, down from ₹21.31 crores sequentially. Year-on-year, whilst the margin improved from 42.50% in Q4 FY25, the sequential deterioration is alarming given the company's historically strong margin profile.
Net profit of ₹10.89 crores in Q4 FY26 declined 12.60% quarter-on-quarter from ₹12.46 crores, and fell 9.25% year-on-year from ₹12.00 crores. The PAT margin compressed to 24.62% from 28.73% in Q3 FY26, a decline of 411 basis points. This represents the lowest quarterly PAT margin since June 2025, when it stood at 25.26%.
Employee costs rose to ₹3.79 crores from ₹4.76 crores in the previous quarter, whilst depreciation increased significantly to ₹4.04 crores from ₹3.89 crores. Interest costs surged dramatically to ₹1.91 crores from ₹0.96 crores in Q3 FY26, reflecting the impact of the company's ₹29.64 crores long-term debt taken on during FY25. Other income fell to ₹0.92 crores from ₹0.42 crores sequentially.
Profitability Concerns: Return Ratios Under Pressure
Whilst Gujarat Themis Biosyn maintains strong historical profitability metrics, recent performance suggests pressure on return ratios. The company's average return on equity (ROE) of 32.79% over recent years positions it favourably within the pharmaceutical sector, though the latest ROE of 18.07% represents a significant decline from historical levels. Similarly, the return on capital employed (ROCE) has compressed to 19.02% in the latest period from an impressive average of 50.79%.
The deterioration in returns can be attributed to multiple factors. First, the company undertook substantial capital expenditure, with fixed assets increasing to ₹40.74 crores in FY25 from ₹35.28 crores in FY24. Second, the introduction of ₹29.64 crores in long-term debt during FY25 has increased the capital base whilst simultaneously elevating interest costs, which surged to ₹1.91 crores in Q4 FY26.
The balance sheet reveals shareholder funds of ₹248.38 crores as of March 2025, up from ₹201.38 crores a year earlier, reflecting retained earnings and a bonus issue that increased share capital from ₹7.26 crores to ₹10.90 crores. However, the company's book value per share of ₹22.79 appears modest compared to the current market price of ₹387.25, resulting in a steep price-to-book ratio of 15.96x.
Margin Compression Alert
Operating margins have declined for two consecutive quarters, falling from 49.47% in Q2 FY26 to 43.77% in Q4 FY26. The 537 basis points sequential contraction in Q4 represents the sharpest quarterly decline in recent periods. Investors should monitor whether this trend continues into FY27, as sustained margin pressure could significantly impact profitability and justify valuation concerns.
Pharmaceutical Sector Context: Navigating Industry Headwinds
Gujarat Themis Biosyn operates in India's pharmaceuticals and biotechnology sector, which has experienced mixed performance in recent quarters. The company's 28.00% one-year stock return significantly outperformed the sector's 11.86% return, generating 16.14 percentage points of outperformance. However, this outperformance has come alongside elevated valuation multiples that now face scrutiny given recent operational challenges.
The pharmaceutical industry in India continues to grapple with pricing pressures in key export markets, regulatory compliance costs, and raw material inflation. Gujarat Themis Biosyn's margin compression in Q4 FY26 mirrors broader industry trends, though the magnitude of the decline appears more severe than sector averages. The company's focus on active pharmaceutical ingredients (APIs) and intermediates exposes it to commodity-like pricing dynamics and intense competition.
Looking at the competitive landscape, Gujarat Themis Biosyn's operating margin of 43.77% (excluding other income) remains healthy compared to many pharmaceutical peers, though the recent trajectory raises concerns. The company's five-year sales compound annual growth rate (CAGR) of 11.22% and operating profit CAGR of 7.23% indicate moderate growth, below the sector's high-growth leaders but above struggling players.
| Company | P/E (TTM) | P/BV | Div Yield | Debt/Equity |
|---|---|---|---|---|
| Guj. Themis Biosyn | 88.31x | 15.96x | 0.17% | 0.23 |
| Senores Pharma | 46.11x | 5.70x | — | 0.20 |
| Innova Captab | 34.60x | 4.47x | 0.23% | 0.27 |
| Advanced Enzyme | 26.26x | 2.58x | 0.32% | -0.41 |
| RPG LifeSciences | 34.49x | 6.14x | 1.07% | -0.36 |
| IOL Chemicals | 24.94x | 2.02x | 0.81% | -0.04 |
Valuation Analysis: Premium Multiples Face Justification Challenge
Gujarat Themis Biosyn trades at a substantial premium to both its peer group and the broader pharmaceutical sector. At 88.31x trailing twelve-month earnings, the stock commands a valuation more than double the sector average P/E of 34x and significantly above all direct peers. The nearest comparable, Senores Pharma, trades at 46.11x earnings, still 48% below Gujarat Themis Biosyn's multiple.
The company's price-to-book ratio of 15.96x also stands well above peer averages of approximately 4.2x. Historically, such premium valuations have been justified by Gujarat Themis Biosyn's superior ROE of 32.79% (average) compared to peer averages around 12%. However, with the latest ROE declining to 18.07%, this valuation premium faces increasing scrutiny.
The enterprise value-to-EBITDA multiple of 59.29x and EV-to-sales ratio of 26.87x further underscore the expensive nature of the valuation. These multiples assume continued margin expansion and accelerated growth, neither of which materialised in Q4 FY26. The stock's dividend yield of just 0.17% provides minimal income support, with the latest dividend of ₹0.67 per share representing a modest 36.63% payout ratio.
From a technical perspective, the stock has retraced 19.23% from its 52-week high of ₹479.45, though it remains 71.54% above its 52-week low of ₹225.75. The current sideways technical trend, which shifted from mildly bullish on May 25, 2026, suggests market participants are reassessing the valuation in light of recent results. Moving averages remain supportive, with the stock trading above all key levels (5-day, 20-day, 50-day, 100-day, and 200-day).
Shareholding Pattern: Stable Promoter Base, Marginal FII Exit
The shareholding structure of Gujarat Themis Biosyn has remained largely stable over recent quarters, with promoter holding steady at 70.86% across the last five quarters ending March 2026. The promoter group comprises Pharmaceutical Business Group (India) Ltd. with 47.02%, Themis Medicare Limited with 23.19%, and smaller holdings through Vividhmargi Trust and individual promoters.
Foreign institutional investor (FII) holding declined marginally to 1.80% in Q4 FY26 from 1.96% in Q3 FY26, representing a sequential reduction of 16 basis points. This follows a more significant decline from 2.95% in Q2 FY26, suggesting some profit-booking by international investors following the stock's strong multi-year run. The number of FII holders stands at 13, indicating limited but diversified foreign interest.
Mutual fund holding has remained unchanged at 1.16% across all reported quarters, with five mutual funds maintaining positions. Insurance companies show zero holding, whilst other domestic institutional investors (DIIs) hold a negligible 0.01%. The non-institutional category, comprising retail and high-net-worth individuals, increased marginally to 26.16% from 26.00% quarter-on-quarter.
| Shareholder Category | Mar'26 | Dec'25 | Sep'25 | QoQ Change |
|---|---|---|---|---|
| Promoter | 70.86% | 70.86% | 70.86% | Flat |
| FII | 1.80% | 1.96% | 2.95% | -0.16% |
| Mutual Funds | 1.16% | 1.16% | 1.16% | Flat |
| Insurance | 0.00% | 0.00% | 0.00% | Flat |
| Other DII | 0.01% | 0.01% | 0.01% | Flat |
| Non-Institutional | 26.16% | 26.00% | 25.01% | +0.16% |
The overall institutional holding of just 2.97% (FII + MF + Insurance + Other DII) remains exceptionally low for a company of Gujarat Themis Biosyn's market capitalisation. This limited institutional participation reflects the concentrated promoter holding and relatively small public float, which contributes to the stock's high beta of 1.77 and elevated volatility of 46.95%.
Stock Performance: Multi-Year Winner Faces Near-Term Headwinds
Gujarat Themis Biosyn has delivered extraordinary long-term returns, though recent performance shows signs of consolidation. Over the past decade, the stock has surged 5,110.86%, generating 4,915.32 percentage points of alpha over the Sensex. The five-year return of 1,037.32% and three-year return of 295.49% similarly demonstrate exceptional wealth creation for long-term shareholders.
However, shorter-term performance reveals a more nuanced picture. The one-year return of 28.00% significantly outpaced the Sensex's -6.40% decline, generating 34.40 percentage points of alpha. Yet, year-to-date performance shows a decline of 12.48% compared to the Sensex's 10.25% fall, indicating recent underperformance of 2.23 percentage points.
The six-month return of -5.87% compares favourably to the Sensex's -9.57% decline, generating 3.70 percentage points of positive alpha. More encouragingly, the three-month return of 22.94% substantially outperformed the Sensex's -7.03% decline, whilst the one-month return of 7.49% and one-week return of 11.39% show strong recent momentum following the Q4 results announcement.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | 11.39% | 1.56% | +9.83% |
| 1 Month | 7.49% | -0.23% | +7.72% |
| 3 Month | 22.94% | -7.03% | +29.97% |
| 6 Month | -5.87% | -9.57% | +3.70% |
| YTD | -12.48% | -10.25% | -2.23% |
| 1 Year | 28.00% | -6.40% | +34.40% |
| 3 Years | 295.49% | 23.62% | +271.87% |
| 5 Years | 1,037.32% | 51.05% | +986.27% |
The stock's risk profile remains elevated, with a beta of 1.77 indicating 77% greater volatility than the broader market. The volatility of 46.95% over the past year significantly exceeds the Sensex's 13.00%, classifying Gujarat Themis Biosyn as a high-risk, high-return investment. The risk-adjusted return of 0.60 over one year, whilst positive, reflects the substantial volatility investors must endure.
Investment Thesis: Quality Company at Stretched Valuation
Gujarat Themis Biosyn presents a complex investment case characterised by strong historical fundamentals undermined by recent operational deterioration and expensive valuation. The company's quality grade of "Good" reflects solid long-term financial performance, with average ROCE of 50.79% and ROE of 32.79% demonstrating efficient capital allocation. The negligible debt-to-EBITDA ratio of 0.17 and strong interest coverage of 62.88x (average) underscore financial stability.
However, the proprietary Mojo Score of 48/100 with a "SELL" rating reflects concerns about near-term prospects. The financial trend classification of "Flat" for Q4 FY26, coupled with deteriorating quarterly profit trends, suggests momentum has stalled. The technical trend shifting to "Sideways" from "Mildly Bullish" reinforces this cautious outlook.
The valuation assessment of "Very Expensive" represents the most significant headwind. At 88.31x trailing earnings, Gujarat Themis Biosyn trades at a 159% premium to the sector P/E of 34x. This premium appears increasingly difficult to justify given Q4 FY26's profit decline and margin compression. The EV/EBITDA multiple of 59.29x and EV/Sales ratio of 26.87x similarly indicate stretched valuations that leave little room for disappointment.
Key Strengths & Risk Factors
KEY STRENGTHS
- Exceptional Long-Term Returns: 5,110.86% return over 10 years demonstrates outstanding wealth creation capability
- Strong Historical Profitability: Average ROCE of 50.79% and ROE of 32.79% reflect efficient capital deployment
- Robust Balance Sheet: Negligible debt-to-EBITDA of 0.17 and strong interest coverage provide financial flexibility
- Stable Promoter Holding: 70.86% promoter stake ensures alignment with minority shareholders
- Quality Upgrade: Recent upgrade to "Good" quality grade validates improving fundamentals
- Sector Outperformance: 28.00% one-year return significantly exceeds pharmaceutical sector's 11.86%
- Consistent Dividend Payer: 36.63% payout ratio demonstrates commitment to shareholder returns
KEY CONCERNS
- Severe Margin Compression: Operating margin fell 537 bps QoQ to 43.77%, lowest in recent quarters
- Profit Decline: Net profit down 12.60% QoQ and 9.25% YoY despite revenue growth
- Expensive Valuation: P/E of 88.31x represents 159% premium to sector average of 34x
- Deteriorating Returns: Latest ROE of 18.07% and ROCE of 19.02% well below historical averages
- Elevated Debt Costs: Interest expense surged to ₹1.91 crores from ₹0.96 crores QoQ
- Limited Institutional Support: Total institutional holding of just 2.97% reflects low conviction
- High Volatility: Beta of 1.77 and volatility of 46.95% indicate significant price risk
Outlook: Critical Monitoring Points Ahead
POSITIVE CATALYSTS
- Margin recovery in Q1 FY27 above 47% would signal operational stabilisation
- Revenue growth acceleration beyond 20% YoY would justify premium valuation
- Return ratios improving towards historical averages (ROE >25%, ROCE >40%)
- Increased institutional participation above 5% would validate investment thesis
- Debt reduction and interest cost normalisation below ₹1 crore quarterly
RED FLAGS
- Further margin compression below 40% would indicate structural profitability issues
- Continued profit decline in Q1 FY27 would confirm negative earnings trajectory
- Additional FII selling beyond current 1.80% stake signals institutional concern
- Debt increase beyond ₹30 crores without corresponding EBITDA growth
- Technical breakdown below 200-day moving average of ₹369.48
The pharmaceutical sector outlook remains mixed, with pricing pressures in export markets and raw material inflation continuing to challenge margins. For Gujarat Themis Biosyn, the Q1 FY27 results will be critical in determining whether Q4 FY26's margin compression represents a temporary blip or the beginning of a structural decline. Management commentary on cost management initiatives and revenue visibility will be closely watched.
From a technical perspective, the stock's recent shift to a sideways trend suggests market participants are reassessing the valuation. Key support lies at the 200-day moving average of ₹369.48, whilst resistance emerges at the 52-week high of ₹479.45. A decisive break below ₹350 could trigger further profit-booking, whilst a move above ₹420 would signal renewed bullish momentum.
The Verdict: Quality Company Facing Valuation Reality Check
Score: 48/100
For Fresh Investors: Avoid initiating positions at current levels. The combination of expensive valuation (88x P/E), deteriorating margins (537 bps QoQ compression), and declining profits (12.60% QoQ fall) presents an unfavourable risk-reward profile. Wait for meaningful valuation correction towards 50-60x P/E or clear evidence of margin recovery before considering entry.
For Existing Holders: Consider booking partial profits, particularly for positions with substantial gains. Whilst the long-term quality remains intact, near-term headwinds from margin pressure and expensive valuation warrant caution. Maintain a trailing stop-loss at ₹350 (10% below current levels) to protect gains. Reassess after Q1 FY27 results for evidence of operational improvement.
Fair Value Estimate: ₹280-300 (28-23% downside from current price), implying a more reasonable 60-65x P/E based on trailing earnings and current margin profile.
Note- ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. The views expressed are those of the author and do not constitute recommendations to buy or sell securities.
